[Skip to Content]

Claim CME

Vaccination

Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease

Educational Objective
To identify the key insights or developments described in this article

1 Credit CME

JAMA Oncology

Published Online: August 11, 2021

Research Letter

Article Information and Disclosures

Thomas A. Ollila, MD^1,2;

Shaolei Lu, MD, PhD^1,3;

Rebecca Masel, MD¹;

Adam Zayac, MD^1,2;

Kimberly Paiva³;

Ralph D. Rogers, MD^1,4;

Adam J. Olszewski, MD^1,2

Author Affiliations

¹Department of Medicine, Alpert Medical School of Brown University, Providence, Rhode Island
²Division of Hematology-Oncology, Rhode Island Hospital, Providence, Rhode Island
³Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Providence, Rhode Island
⁴Division of Infectious Disease, Rhode Island Hospital, Providence, Rhode Island

Read article on JAMA Network

Read Article Claim CME

The effectiveness of COVID-19 vaccination remains unknown in patients with hematologic malignant disease who have an impaired humoral immunity from both treatment and disease. Phase 3 registration studies of COVID-19 vaccines excluded patients with immunosuppression or immunosuppressive therapies.¹^,2 Despite this, professional organizations suggest vaccination, or even its prioritization, for patients with cancer.³ As the US Centers for Disease Control loosens pandemic-related precautions for vaccinated people, a better understanding of the vaccine response among patients with hematologic malignant disease is critical.

Claim CME

Sign in to take quiz and track your certificates

Buy This Activity

Article Information

Accepted for Publication: July 12, 2021.

Published Online: August 11, 2021. doi:10.1001/jamaoncol.2021.4381

Corresponding Author: Thomas A. Ollila, MD, Alpert Medical School of Brown University, Rhode Island Hospital, George Bldg, Ste 310, 593 Eddy St, Providence, RI 02903 (thomas_ollila@brown.edu).

Author Contributions: Dr Ollila had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Ollila, Lu, Rogers, Olszewski.

Acquisition, analysis, or interpretation of data: Ollila, Lu, Masel, Zayac, Paiva, Olszewski.

Drafting of the manuscript: Ollila, Zayac, Paiva, Olszewski.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Olszewski.

Administrative, technical, or material support: Ollila, Lu, Paiva, Rogers, Olszewski.

Supervision: Ollila, Olszewski.

Conflict of Interest Disclosures: Dr Olszewski reported research funding from Genentech, TG Therapeutics, Celldex Pharmaceuticals, and Precision Bio; grants from Acrotech Pharma, Adaptive Biotechnologies outside the submitted work. No other disclosures were reported.

Additional Contributions: In addition to the listed authors, we acknowledge the following individuals for their assistance with this study, none of whom were compensated for his or her contributions and all of whom agree to include their names here: John L. Reagan, MD (Brown Alpert School of Medicine); Peter Barth, MD (Brown Alpert School of Medicine); Rabin Niroula, MD; Gerard J. Nau, MD, PhD (Brown Alpert School of Medicine); Rani Chudasama, MD (Brown Alpert School of Medicine); Inna Yakirevich, NP (Division of Hematology/Oncology, Rhode Island Hospital); and Christopher Elco, MD, PhD (Brown Alpert School of Medicine).

AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
1.00 credit toward the CME [and Self-Assessment requirements] of the American Board of Surgery’s Continuous Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.